The start-up designs, manufactures and markets bone regeneration solutions in the dental, maxillofacial and orthopaedic fields.
The multinational Nobel Biocare has acquired Barcelona-based start-up Mimetis Biomaterials, a spin-off from the Biomaterials, Biomechanics and Tissue Engineering (BBT) group of the Biomedical Engineering Research Centre (CREB) at the Universitat Politècnica de Catalunya – BarcelonaTech (UPC).
Mimetis is the manufacturer of MimetikOss Granules and MimetikOss 3D, the first biomimetic synthetic bone substitutes that mimic the mineral part of bone, contributing to the formation of highly vascularised bone. In addition, MimetikOss 3D enables a customised design for each patient, a highly versatile solution in the most complex cases of bone regeneration. In this way, a highly demanded technology with enormous potential in the field of bone replacement is made available to the medical community.
Founded in 2013 by researchers David Pastorino, Yassine Maazouz, Xavier Gil and Maria Pau Ginebra, the team has developed a technology inspired by the natural process of bone formation, which gives it a better biological response than conventional bone substitutes. With a track record of more than 20 years of research, the Biomaterials, Biomechanics and Tissue Engineering (BBT) group at CREB UPC has focused its work on different strategies for the application of biomaterials in regenerative medicine, which has led, among other advances, to the development in recent years of scaffolds for bone tissue engineering through 3D printing technologies, including the design of bioactive inks that allow the manufacture of advanced structures based on biomimetic calcium phosphates, which allow the incorporation of biologically active substances. “We continue to work on the research of new technologies to improve bone regeneration, with special emphasis on 3D printing,” says Maria Pau Ginebra, Director of the Biomaterials Division of CREB UPC and one of the founders of Mimetis Biomaterials.
BBT Research group prioritises participation in quality national and European research projects and research on priority topics such as cancer, osteoporosis, research in relation to cardiovascular diseases or the improvement of dental implants and joint prostheses. Its current lines of research focus on plasmas for biomedical applications, advanced metallic biomaterials and functionalisation as well as biomaterials for bone regeneration.
This project is co-financed by the European Union through the European Regional Development Fund (ERDF).